国際的なRAI内用療法の現状と本邦における展望
甲状腺腫瘍診療ガイドライン改訂によりRAI内用療法の定義が厳密化されることとなった。新たにアジュバントというカテゴリーが明確化された。改訂ガイドラインに沿った診療をしっかりと行うためには，国内の内用療法環境をさらに改善する必要がある。RAI内用療法は手法ができあがっているように思えるが，実は未解決の問題が種々残っている。...
Saved in:
| Published in | 日本内分泌・甲状腺外科学会雑誌 Vol. 35; no. 3; pp. 192 - 195 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Japanese |
| Published |
日本内分泌外科学会・日本甲状腺外科学会
2018
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2186-9545 |
| DOI | 10.11226/jaesjsts.35.3_192 |
Cover
| Abstract | 甲状腺腫瘍診療ガイドライン改訂によりRAI内用療法の定義が厳密化されることとなった。新たにアジュバントというカテゴリーが明確化された。改訂ガイドラインに沿った診療をしっかりと行うためには，国内の内用療法環境をさらに改善する必要がある。RAI内用療法は手法ができあがっているように思えるが，実は未解決の問題が種々残っている。 |
|---|---|
| AbstractList | 甲状腺腫瘍診療ガイドライン改訂によりRAI内用療法の定義が厳密化されることとなった。新たにアジュバントというカテゴリーが明確化された。改訂ガイドラインに沿った診療をしっかりと行うためには，国内の内用療法環境をさらに改善する必要がある。RAI内用療法は手法ができあがっているように思えるが，実は未解決の問題が種々残っている。 |
| Author | 絹谷, 清剛 |
| Author_xml | – sequence: 1 fullname: 絹谷, 清剛 organization: 金沢大学医薬保健研究域医学系核医学 |
| BookMark | eNo9j81Kw0AcxPdQwVr7Ar5D6u7_n90kJ6nFj0JBED2HTTbRhlol24vHFPVQDyLYg23PUlQEEbzpyyxt6FsY8eMyAzPDwG-FlLqn3YiQNUZrjAGI9URGOtE9XUNeQ595UCJlYK6wPG7zZVLVOqGUIqAHrlsmG7Pxx2I0zkcXJnvcrzdnV5f53TS_78_fhiZ7yW8-88G7yabzyfOi_2CyJ5MNTHZr-tez1-F8Ml4lS7Hs6Kj66xVyuL110Ni1Wns7zUa9ZSWA6FhebAvOpYBIAYUQYuUIh7pBoGJG7VABKCcuAoAw4EIJ4CxGEQKCEuhSiRWy-fNbsMmjyD9L2ycyPfdl2muHncj_w_aR-_gtBfl_GR7LtFjgF1yvbHs |
| ContentType | Journal Article |
| Copyright | 2018 日本内分泌外科学会・日本甲状腺外科学会 |
| Copyright_xml | – notice: 2018 日本内分泌外科学会・日本甲状腺外科学会 |
| DOI | 10.11226/jaesjsts.35.3_192 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| EndPage | 195 |
| ExternalDocumentID | article_jaesjsts_35_3_35_192_article_char_ja |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS JSF KQ8 RJT |
| ID | FETCH-LOGICAL-j2337-9f4655a62ed202c2fd76708bbdf104cd22d7f70822cb56d6251f36c232d6380a3 |
| ISSN | 2186-9545 |
| IngestDate | Wed Sep 03 06:20:56 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | Japanese |
| License | https://creativecommons.org/licenses/by-nc/4.0/deed.ja |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j2337-9f4655a62ed202c2fd76708bbdf104cd22d7f70822cb56d6251f36c232d6380a3 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jaesjsts/35/3/35_192/_article/-char/ja |
| PageCount | 4 |
| ParticipantIDs | jstage_primary_article_jaesjsts_35_3_35_192_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2018 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – year: 2018 text: 2018 |
| PublicationDecade | 2010 |
| PublicationTitle | 日本内分泌・甲状腺外科学会雑誌 |
| PublicationTitleAlternate | 内分泌甲状腺外会誌 |
| PublicationYear | 2018 |
| Publisher | 日本内分泌外科学会・日本甲状腺外科学会 |
| Publisher_xml | – name: 日本内分泌外科学会・日本甲状腺外科学会 |
| References | 8. 絹谷清剛：環境改善に向けた活動．日内分泌・甲状腺外会誌 30：130-136，2013 15. Oh SW, Moon S-H, Park DJ, et al.: Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer. Eur J Nucl Med Mol Imaging 38: 1798-1805, 2011 4. Suman P, Wang CH, Abadin SS, et al.: Timing of radioactive iodine therapy does not impact overall survival in high-risk papillary thyroid carcinoma. Endocr Pract 22: 822-831, 2016 14. Plyku D, Hobbs RF, Huang K, et al.: Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer. J Nucl Med 58: 1146-1154, 2017 17. 核医学診療推進国民会議：核医学診療推進国民会議 http://www.ncnmt.jp/ 平成30年７月24日参照 2. Higashi T, Nishii R, Yamada S, et al.: Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma:a retrospective statistical analysis of 198 cases. J Nucl Med 52: 683-689, 2011 11. Deandreis D, Rubino C, Tala H, et al.: Comparison of empiric versus whole-body/-blood clearance dosimetry based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer. J Nucl Med 58: 717-722, 2017 12. Jentzen W1, Nahum AE, Bockisch A, et al.: Fixed 3.7-GBq 131I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History. J Nucl Med 58: 1530, 2017 1. 日本アイソトープ協会 医学・薬学部会 全国核医学診療実態調査専門委員会: 第８回全国核医学診療実態調査報告書．RADIOISOTOPE67：339-387, 2018 9. Tuttle RM: Controversial issues in thyroid cancer management. J Nucl Med 2018 Apr 13. pii: jnumed.117.192559. doi: 10.2967/jnumed.117.192559. [Epub ahead of print] 13. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, et al.: Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer. Endocr Pract 19:139-48, 2013 6. Tsirona S, Vlassopoulou V, Tzanela M, et al.: Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer. Clin Endocrinol (Oxf) 80: 459-463, 2014 10. Haugen BR, Alexander EK, Bible KC, et al.: 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26: 1-133, 2016 16. Oh JM, Kalimuthu S, Gangadaran P, et al.: Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system. Oncotarget 9: 7075-7087, 2018 5. Suman P, Wang CH, Moo-Young TA, et al.: Timing of adjuvant radioactive iodine therapy does not affect overall survival in low- and intermediate-risk papillary thyroid carcinoma. Am Surg 82: 807-814, 2016 7. Li H, Zhang Y-Q, Wang C, et al.: Delayed initial radioiodine therapy related to imcomplete response in low- to intermediate-risk differential thyroid cancer. Clin Endocl 88: 1-606, 2018 3. Scheffel RS, Zanella AB, Dora JM, et al.: Timing of radioactive iodine administration does not influence outcomes in patients with differentiated thyroid carcinoma. Thyroid 26: 1623-1629, 2016 |
| References_xml | – reference: 5. Suman P, Wang CH, Moo-Young TA, et al.: Timing of adjuvant radioactive iodine therapy does not affect overall survival in low- and intermediate-risk papillary thyroid carcinoma. Am Surg 82: 807-814, 2016 – reference: 17. 核医学診療推進国民会議：核医学診療推進国民会議 http://www.ncnmt.jp/ 平成30年７月24日参照 – reference: 3. Scheffel RS, Zanella AB, Dora JM, et al.: Timing of radioactive iodine administration does not influence outcomes in patients with differentiated thyroid carcinoma. Thyroid 26: 1623-1629, 2016 – reference: 9. Tuttle RM: Controversial issues in thyroid cancer management. J Nucl Med 2018 Apr 13. pii: jnumed.117.192559. doi: 10.2967/jnumed.117.192559. [Epub ahead of print] – reference: 14. Plyku D, Hobbs RF, Huang K, et al.: Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer. J Nucl Med 58: 1146-1154, 2017 – reference: 8. 絹谷清剛：環境改善に向けた活動．日内分泌・甲状腺外会誌 30：130-136，2013 – reference: 10. Haugen BR, Alexander EK, Bible KC, et al.: 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26: 1-133, 2016 – reference: 15. Oh SW, Moon S-H, Park DJ, et al.: Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer. Eur J Nucl Med Mol Imaging 38: 1798-1805, 2011 – reference: 7. Li H, Zhang Y-Q, Wang C, et al.: Delayed initial radioiodine therapy related to imcomplete response in low- to intermediate-risk differential thyroid cancer. Clin Endocl 88: 1-606, 2018 – reference: 16. Oh JM, Kalimuthu S, Gangadaran P, et al.: Reverting iodine avidity of radioactive-iodine refractory thyroid cancer with a new tyrosine kinase inhibitor (K905-0266) excavated by high-throughput NIS (sodium iodide symporter) enhancer screening platform using dual reporter gene system. Oncotarget 9: 7075-7087, 2018 – reference: 11. Deandreis D, Rubino C, Tala H, et al.: Comparison of empiric versus whole-body/-blood clearance dosimetry based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer. J Nucl Med 58: 717-722, 2017 – reference: 6. Tsirona S, Vlassopoulou V, Tzanela M, et al.: Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer. Clin Endocrinol (Oxf) 80: 459-463, 2014 – reference: 13. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, et al.: Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer. Endocr Pract 19:139-48, 2013 – reference: 4. Suman P, Wang CH, Abadin SS, et al.: Timing of radioactive iodine therapy does not impact overall survival in high-risk papillary thyroid carcinoma. Endocr Pract 22: 822-831, 2016 – reference: 12. Jentzen W1, Nahum AE, Bockisch A, et al.: Fixed 3.7-GBq 131I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History. J Nucl Med 58: 1530, 2017 – reference: 1. 日本アイソトープ協会 医学・薬学部会 全国核医学診療実態調査専門委員会: 第８回全国核医学診療実態調査報告書．RADIOISOTOPE67：339-387, 2018 – reference: 2. Higashi T, Nishii R, Yamada S, et al.: Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma:a retrospective statistical analysis of 198 cases. J Nucl Med 52: 683-689, 2011 |
| SSID | ssj0003239288 ssib012362452 |
| Score | 2.1301656 |
| Snippet | 甲状腺腫瘍診療ガイドライン改訂によりRAI内用療法の定義が厳密化されることとなった。新たにアジュバントというカテゴリーが明確化された。改訂ガイドラインに沿った診... |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 192 |
| SubjectTerms | アジュバント アブレーション 内用療法 放射性ヨウ素 |
| Title | 国際的なRAI内用療法の現状と本邦における展望 |
| URI | https://www.jstage.jst.go.jp/article/jaesjsts/35/3/35_192/_article/-char/ja |
| Volume | 35 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 日本内分泌・甲状腺外科学会雑誌, 2018, Vol.35(3), pp.192-195 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library issn: 2186-9545 databaseCode: KQ8 dateStart: 20120101 customDbUrl: isFulltext: true dateEnd: 99991231 titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html omitProxy: true ssIdentifier: ssj0003239288 providerName: Colorado Alliance of Research Libraries |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR09bxMx9NSWhQWBAPGtDni8cGffnW0xIDu9qjAggVqp2yl3zg0ZCqLpwpYKGMqAkOhA0xlVgJAQEhuI_3JKov4L3vN9EBSGhi6nF78PP_v549mx_RzntuCd3BjRdbOcRW6QZb6bmjB3s5RDqu9nQXnK92G0thE82Aw3FxZ_TZ1a2umnrez5P--V_I9VIQ3sirdk57BsIxQSAAb7whcsDN8T2ZjEIZGa6BUSSyIVwjFHQAQkZuAkEqUeq_tIJiIiQosNiBIWkERQEkdEMyLDmj5GlFglugQU0VGNEkgs20S1MTvgVQ1KVwDQl4D0LUCJ0Ji79m0Wll3qaYfYJnKiwinhjbYACIRLJUXbymRE66ogmk4pKZBFK-RSAZERohS3mkDKitUWWNpYP1hd2qIEVBFIrtsdMmkQIxGjPaI5tkGrgKhVknURqs2SamTHhj1naU6iaVPiWcmnqoM_MwDGC3NlWL63WU9X5esuVbdkU3OPXwYVrNwYv4xdOjtDUhvUs9fpbve2-9stFrZY0rD-9fJ41a6TmjZhYcLwA-RJjcTLgUCx6JyhHHw9PBbxqBnR8Wkf_Gu_2fVkFPxxGwy2KVtzk41Gd2a0Ar8QfjcnLK3Tt37eOVet1pZVqcUFZ6HXuejcGw1_HB8MJwcvisFH6F6jVy8n744m73fH3_aLwZfJm5-Tve_F4Gh8-Pl490Mx-FQM9orB22L39ejr_vhweMnZWI3X22tuFYfE7VHGuCtzfGSwE9GuoR7NaG54xD2Rpib3vSAzlBqecwydkKVhZCJYMsDAl8FaxcDs5nXYZWdp68lW94qz3OlyT5qMG5j7YClgRBD6GALCeF4GnrZ_1blbljd5Wj42k8xjhGun4r7unMUuU-4v3nCW-s92ujfB4-6nt6xRfwMn26k1 |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E5%9B%BD%E9%9A%9B%E7%9A%84%E3%81%AARAI%E5%86%85%E7%94%A8%E7%99%82%E6%B3%95%E3%81%AE%E7%8F%BE%E7%8A%B6%E3%81%A8%E6%9C%AC%E9%82%A6%E3%81%AB%E3%81%8A%E3%81%91%E3%82%8B%E5%B1%95%E6%9C%9B&rft.jtitle=%E6%97%A5%E6%9C%AC%E5%86%85%E5%88%86%E6%B3%8C%E3%83%BB%E7%94%B2%E7%8A%B6%E8%85%BA%E5%A4%96%E7%A7%91%E5%AD%A6%E4%BC%9A%E9%9B%91%E8%AA%8C&rft.au=%E7%B5%B9%E8%B0%B7%2C+%E6%B8%85%E5%89%9B&rft.date=2018&rft.pub=%E6%97%A5%E6%9C%AC%E5%86%85%E5%88%86%E6%B3%8C%E5%A4%96%E7%A7%91%E5%AD%A6%E4%BC%9A%E3%83%BB%E6%97%A5%E6%9C%AC%E7%94%B2%E7%8A%B6%E8%85%BA%E5%A4%96%E7%A7%91%E5%AD%A6%E4%BC%9A&rft.issn=2186-9545&rft.volume=35&rft.issue=3&rft.spage=192&rft.epage=195&rft_id=info:doi/10.11226%2Fjaesjsts.35.3_192&rft.externalDocID=article_jaesjsts_35_3_35_192_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2186-9545&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2186-9545&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2186-9545&client=summon |